APR 14, 2018 5:14 PM PDT

First Hydrocarbon Peptide Therapeutic for Lethal Leukemia

WRITTEN BY: Nouran Amin

 

Acute myeloid leukemia (AML) is a lethal cancer of the blood and bone marrow. It affects a group of white blood cells known as the myeloid cells, which develop into the various types of mature blood cells, such as red blood cells, white blood cells and platelets. AML is caused DNA damage in the developing cells of the bone marrow. When this damage occurs, production of blood cells is altered.

Now, investigators at Albert Einstein College of Medicine researchers have found an experimental peptide drug that may treat AML. Researchers describe how this peptide functions at the molecular level which encourages a clinical study for advanced stage AML as well as advanced myelodysplastic syndrome. During the preclinical phase, the peptide called ALRN-6924, was seen to triple the survival rate in animal studies with transplanted human leukemic cells. "Most experimental drugs for leukemia achieve an increase in survival of only a few days in these preclinical models. Even more importantly, ALRN-6924 effectively cured about 40 percent of the treated mice," says lead study investigator and professor of cell biology and medicine at Einstein.

ALRN-6924, also known as a stapled alpha-helical peptide, was developed by Aileron Therapeutics Inc. Its helical structure is stabilized using hydrocarbon “staples, the staples prevents the peptides from being targeted by enzymes before reaching their own target. It works to target p53, which is a tumor-suppressor protein but is inactivated in many forms of cancer including AML. The inactivation is due to a mutation in its encoding gene. The drug was developed to block the function of two naturally occurring proteins, MDMX and MDM2, whose overexpression inactivates p53, allowing cancer cells to continuously proliferate.

VIDEO: IN THIS VIDEO OF CANCER CELLS, EACH FLICKERING WHITE SPOT MEANS THAT THE STAPLED PEPTIDE DRUG HAS TURNED ON PREVIOUSLY-INACTIVATED P53 TUMOR SUPPRESSOR PROTEIN. CREDIT: ADRIEN SENECAL, ROBERT H. SINGER, AND ROBERT A. COLEMAN (ALBERT EINSTEIN COLLEGE OF MEDICINE

To study in-depth the mechanisms of action, Steidl and other investigators confirmed that ALRN-6924 inhibitors both MDMX and MDM2 by blocking their function with p53 in AML cells. The inhibition was seen in both more mature AML cells and the immature stem cells. “This is important,” explains Steidl, “because AML is driven by stem cells–and if you don’t target stem cells, the disease will come back very quickly.”

In AML patients administered the drug, the molecular mechanistic changes of ALRN-6924 was observed in their blood cells. “This test was not designed to assess the efficacy of the drug in humans–that has to be done in a proper clinical trial,” says Dr Steidl. “Our goal was to determine whether it can hit the desired target in human cells in a clinical setting, which it did in this individual.” ALRN-6924 is the first hydrocarbon-stapled peptide treatment to be tested in patients.

Sources: Journal of Science & Translational Medicine, Medical Xpress

About the Author
BS/MS
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
APR 20, 2022
Cancer
"Saturating" the Liver with Chemotherapy to Treat Cancer
APR 20, 2022
"Saturating" the Liver with Chemotherapy to Treat Cancer
Uveal melanoma is a rare type of cancer that grows in the melanin, the dark-colored pigment of the eye. About  ...
APR 25, 2022
Health & Medicine
Sex differences in association between cannabis use and diabetes
APR 25, 2022
Sex differences in association between cannabis use and diabetes
A preprint published in Cannabis Cannabinoid Research examined the association between cannabis use and diabetes to dete ...
MAY 13, 2022
Drug Discovery & Development
Multiple Mental Health Diagnoses are Increasingly Common. Why?
MAY 13, 2022
Multiple Mental Health Diagnoses are Increasingly Common. Why?
Mental illness has become increasingly common. The number of people with anxiety and depression, specifically, has stead ...
MAY 26, 2022
Drug Discovery & Development
Sonic Hedgehog gene speeds up large-scale bone regeneration
MAY 26, 2022
Sonic Hedgehog gene speeds up large-scale bone regeneration
Some species of lizards can detach their tails from their bodies when they feel threatened. This common defense mechanis ...
JUN 06, 2022
Drug Discovery & Development
New Antibiotic Shows Promise Against Treatment-Resistant Tuberculosis
JUN 06, 2022
New Antibiotic Shows Promise Against Treatment-Resistant Tuberculosis
A new class of antibiotics has shown promise in preclinical trials against drug-resistant tuberculosis. The correspondin ...
JUN 26, 2022
Drug Discovery & Development
Acupuncture Alleviates Chronic Tension Headaches in Randomized Controlled Trial
JUN 26, 2022
Acupuncture Alleviates Chronic Tension Headaches in Randomized Controlled Trial
Results from a randomized controlled trial suggest that acupuncture may relieve symptoms of chronic tension-type headach ...
Loading Comments...